Manages manifestations of psychotic disorders. ANDA 214534, held by Dr Reddys. Fluphenazine Hydrochloride.
As of Nov 16, 2026, ANDA 214534 (Fluphenazine Hydrochloride), held by Dr Reddys, was first approved by FDA on Jan 7, 2021, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Fluphenazine hydrochloride tablets are indicated in the management of manifestations of psychotic disorders. Fluphenazine hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 7, 2021 | Original application | Approved | None posted |
| Fluphenazine Hydrochloride1MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride2.5MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride5MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Fluphenazine Hydrochloride10MG · tablet;oral | Fluphenazine Hydrochloride | Rx |
| Jan 22, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 7, 2021 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters